IDP Pharma closes a funding round for 2 million euros Blog Post

IDP Pharma, founded in 2015 and with headquarters at the Barcelona Science Park (PCB) has raised, during its first operative year, over 2 million euros from public and private capital. The biopharmaceutical company –specializes in the development of drugs for cancer treatment directed to a new class of therapeutic targets: IDPs– will appoint this capital to continue the preclinical development of their most advanced products: two first-in-class molecules with antitumor activity for Multiple Myeloma, the second most common blood cancer

 

Researchers froms IBEC and UB have collaborated in the definition of a new kind of indicators for bacterial virulence Blog Post

Researchers and the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona (UB) together with their collaborators from the University of Santiago de Compostela (USC), the Institute of Medical Microbiology and Hygiene (University of Lübeck) and German Center for Infection Research (DZIF) have determined a new kind of indicators for bacterial virulence which can help detect and preventing infection outbreaks caused by Escherichia coli.

 

Eugin grows its business to 14,000 treatments per year Blog Post

Eugin Clinic performed 13,885 assisted reproduction treatments in 2015, which places it as one of the European leaders in the sector. The international centre, which has its basic research laboratory at the Barcelona Science Park (PCB), performs 10% of the treatments by means of egg donation from all over Europe and their success rates, which are verified by the prestigious German certification agency, TÜV, confirm that 9 in10 women achieve pregnancy. Eugin is also undertaking a large number of scientific projects with leading research centres and six European universities, including the University of Barcelona (UB).

 

Mind the Byte and Sequentia take part in a trade mission in Massachusetts Blog Post

Mind the Byte and Sequentia Biotech, both based at the Barcelona Science Park (PCB), have been two of the 10 Catalan companies that participated last week in a trade mission in the state of Massachusetts (US) to search for business opportunities in the fields of digital health and big data applied to life sciences. The trade mission was organized by the Government of Catalonia through ACCIÓ, the agency for business competitiveness, and Biocat coinciding with Bio-IT World Conference & Expo, one of the largest and most important events in the US in the field of ICTs in the health sector.  

 

Pharma companies innovate through talent management and tech transfer Blog Post

The fourth SciCloud (Scientific Cloud Conference) event held by Mind the Byte, in collaboration with the Barcelona Science Park (PCB) and CataloniaBio, on the 30th of March focused on the innovation models that four emblematic Catalan pharmaceutical companies (Uriach, Ferrer, Kern Pharma and Reig Jofre) use to compete on the global market and on how technology transfer is being successfully promoted through initiatives like Tech & Business Innovation (TBI) and at the Polytechnic University of Valencia. 

 

PCB presents the BATX2LAB awards Blog Post

Yesterday, Wednesday 9th March, the Barcelona Science Park organized the awards ceremony of the best research works of the BATX2LAB program –a project fostered as part of its program ‘Research in Society‘–, which this year has been organized with the support of the Municipal Institute of Education of the Barcelona City Council (IMEB). The event took place at the Dolors Aleu Hall at PCB bringing together more than 100 attendees.

 

GreeNC, the first database of non-coding RNAs in plants Blog Post

Sequentia Biotech, a company based at the Barcelona Science Park (PCB), has developed the first database of non-coding RNAs in vegetal species: GreeNC. It is a repository of more than 200,000 lncRNAs annotated in 37 plant species and 6 algae that provides information about the sequence, genomic coordinates, coding potential, and folding energy for all lncRNAs identified. 

 

Jordi Naval: “I think both researchers and companies should expand their scope of vision and ask themselves where they are headed” Blog Post

Jordi Naval takes over the management of Fundació Bosch i Gimpera (FBG) with a clear objective: building a climate of trust and interaction among researchers, investors and the productive fabric. A very ambitious challenge that Naval faces with the skill and resolution that his double ‘expertise’ as both, a scientist and entrepreneur, has given him.